Alnylam-JPM-20240108.pdf

1、1 2024 Alnylam Pharmaceuticals,Inc.January 8,2024Yvonne Greenstreet,MBChBChief Executive Officer42ndAnnual J.P.Morgan Healthcare Conference2Alnylam Forward Looking StatementsThis presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sect

2、ion 21E of the SecuritiesExchange Act of 1934.All statements other than historical statements of fact regarding Alnylams expectations,beliefs,goals,plans or prospects including,without limitation,expectations regarding Alnylams aspiration to become a top-tier biotech company and the planned achievem

3、ent of its“Alnylam P5x25”strategy,the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs,Alnylamsability to obtain approval for new commercial products or additional indications for its existing products,and Alnylams projecte

4、d commercial and financialperformance,should be considered forward-looking statements.Actual results and future plans may differ materially from those indicated by theseforward-looking statements as a result of various important risks,uncertainties and other factors,including,without limitation,risk

5、s and uncertaintiesrelating to Alnylams ability to successfully execute on its“Alnylam P5x25”strategy;Alnylams ability to discover and develop novel drug candidates anddelivery approaches and successfully demonstrate the efficacy and safety of its product candidates;the pre-clinical and clinical res

6、ults for Alnylamsproduct candidates,including topline results from the Companys HELIOS-B Phase 3 study of vutrisiran;actions or advice of regulatory agencies andAlnylams ability to obtain and maintain regulatory approval for its product candidates,as well as favorable pricing and reimbursement;succe